Report #2897557

Received May 22, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 56 yrs
State: —
Recovered: Not recovered
Vaccinated: May 15, 2026
Onset: May 16, 2026
Days to onset: 1
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	NT357	—

Symptoms (2)

Injection site erythemaInjection site swelling

Symptom narrative

swelling at injection site; Redness at injection site; This non-serious case was reported by a consumer and described the occurrence of injection site swelling in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number NT357) for prophylaxis. On 15-MAY-2026, the patient received Shingrix 50 ug. On 16-MAY-2026, 1 days after receiving Shingrix, the patient experienced injection site swelling (Verbatim: swelling at injection site) and injection site erythema (Verbatim: Redness at injection site). The outcome of the injection site swelling and injection site erythema were not resolved. It was unknown if the reporter considered the injection site swelling and injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site swelling and injection site erythema to be related to Shingrix.